Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Trial Profile

A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Carboplatin; Paclitaxel
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms KEYNOTE-021
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Sep 2019 According to an Merck & Co media release, results of pooled analysis of a subgroup of patients with advanced nonsquamous and squamous non-small cell lung cancer whose tumors do not express PD-L1 (tumor proportion score [TPS] <1%) from three trials (KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 (Cohort G)) were presented at the IASLC 2019 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain (Abstract #MA25.01).
    • 10 Sep 2019 Results (n=70) assessing efficacy of pembrolizumab in patients with metastatic non-small cell lung cancer, presented at the 20th World Conference on Lung Cancer.
    • 10 Sep 2019 Results of a post-hoc pooled analysis of KEYNOTE-021, KEYNOTE-189 and KEYNOTE-407 assessing pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced NSCLC and no PD-L1 expression, presented at the 20th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top